An association between metabolic syndrome and the estimated glomerular filtration rate

Internal Medicine

Volumn 47, Issue 15, 2008, Pages 1399-1406

  Kawamoto, Ryuichi ^a   Kohara, Katsuhiko ^b   Tabara, Yasuharu ^b   Miki, Tetsuro ^b  

^a Nomura Municipal Hospital   (Japan)

^b EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CKD; eGFR; Metabolic syndrome; Renal function; Risk factor

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG USE; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; JAPANESE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIPLE LINEAR REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; BLOOD; BLOOD PRESSURE; CHRONIC DISEASE; ETHNOLOGY; JAPAN; KIDNEY DISEASE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; STATISTICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL, HDL; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; JAPAN; KIDNEY DISEASES; LINEAR MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS;

EID: 53749092499     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.1202     Document Type: Article

References (45)

1. Weiner DF, Tighiouart H, Stark PC, et al. Kidney disease as a risk factor for recurrent cardiovascular and mortality. Am J Kidney Dis 44: 198-206, 2004.
2. Meisinger C, Doring A, Lowel H: KORA Study Group. Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. Eur Heart J 27: 1245-1250, 2006.
3. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67: 2089-2100, 2005.
4. Imai E, Horio M, Iseki K, et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol 11: 156-163, 2007.
5. Kekeuchi H, Saitoh S, Takagi S, et al. Metabolic syndrome and insulin resistance in Japanese Male-Tanno-Soubetsu Study. J Japan Diab Soc 46: 739-744, 2003 (in Japanese, Abstract in English).
6. Shiwaku K, Nogi A, Kitajima K, et al. Prevalence of the metabolic syndrome using the modified ATP III definitions for workers in Japan, Korea and Mongolia. J Occup Health 47: 126-135, 2005.
7. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. San Antonio Heart Study. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 26: 3153-3159, 2003.
8. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 28: 385-390, 2005.
9. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288: 2709-2716, 2002.
10. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502, 1972.
11. Imai E, Horio M, Nitta K, et al. Modification of the Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis 50: 927-937, 2007.
12. The Japanese Society of Nephrology: Japanese version of GFR estimation. http://www.jsn.or.jp: Updated Oct 29, 2007.
13. Examination committee of criteria for diagnosis of metabolic syndrome in Japan. Definition and criteria for the diagnosis of metabolic syndrome. J Jpn Soc Int Med 94: 794-809, 2005 (in Japanese, Abstract in English).
14. The examination Committee of Criteria for "Obesity Disease" in Japan. Japan Society for Study of Obesity. New criteria for obesity disease in Japan. Circ J 66: 987-992, 2002.
15. Ota T, Takamura T, Hirai N, Kobayashi K. Preobesity in World Health Organization classification involves the metabolic syndrome in Japanese. Diabetes Care 25: 1252-1253. 2002.
16. The IDF consensus worldwide definition for the metabolic syndronic. Part 4: Worldwide definition for use in clinical practice. Available at www.idf.org/webdata/docs/IDFmetasyndromedefinition.pdf. Accessed May 11, 2007.
17. Zhang L, Zuo L, Wang F, et al. Metabolic syndrome and chronic kidney disease in a Chinese population aged 40 years and older. Mayo Clin Proc 82: 822-827, 2007.
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel oil Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285: 2486-2497, 2001.
19. Hao Z, Konta T, Takasaki S, et al. The association between microalbuminuria and metabolic syndrome in the general population in Japan: the Takahata study. Intern Med 46: 341-346, 2007.
20. Ninomiya T, Kiyohara Y, Kubo M, et al. Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis 48: 383-391, 2006.
21. Tozawa M, Iseki C, Tokashilki K, et al. Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults. Hypertens Res 30: 937-943, 2007.
22. Kitiyakara C, Yamwong S, Cheepudomwit S, et al. The metabolic syndrome and chronic kidney disease in a Southeast Asian cohort. Kidney Int 71: 693-700, 2007.
23. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onsel kidney disease in a community-based population. JAMA 291: 844-850, 2004.
24. Gelber RP, Kurth T, Kausz AT, et al. Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis 46: 871-880, 2005.
25. Kawamoto R, Kohara K, Tabara Y, et al. An Association between Body Mass Index and Estimated Glomerular-Filtration Rate. Hypertens Res 31: 2008 in press.
26. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289: 76-79, 2003.
27. Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ. Risk of end-stage renal disease in diabetes mellitus: A prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 278: 2069-2074, 1997.
28. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and endstage renal disease in men. N Engl J Med 334: 13-18, 1996.
29. Nakai S, Wada A, Kitaoka T, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2004). Their Apher Dial 10: 476-497, 2006.
30. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557-1565, 2002.
31. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288: 2015-2022, 2002.
32. Drüeke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products and carotid artery intima-media thickness in end-stage renal disease. Circulation 106: 2212-2217, 2002.
33. Mathew B, Patel SB, Reams GP, Freeman RH, Spear RM, Villarreal D. Obesity-hypertension: emerging concepts in pathophysiology and treatment. Am J Med Sci 334: 23-30, 2007.
34. Masuo K, Mikami H, Itoh M, Ogihara T, Tuck ML. Sympathetic activity and body mass index contribute to blood pressure levels. Hypertens Rev 23: 303-110, 2000.
35. Knight SF, Imig JD. Obesity, insulin resistance, and renal function. Microcirculation 14: 349-362, 2007.
36. Engeli S, Gorzelniak K, Kreutz R, Runkel N, Distler A, Sharma AM. Co-expression of renin-angiotensin system genes in human adipose tissue. J Hypertens 17: 555-560, 1999.
37. Honda H, Qureshi AR, Heimburger O, et al. Serum albumin. C-reactive protien, interleukin 6, and fetuin-A as predictors of malnutrition, cardiovascular disease; and mortality in patients with ESRD. Am J Kidney Dis 47: 139-148, 2006.
38. Chan DT, Irish AB, Dogra GK, Watts GF. Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. Atherosclerosis 196: 823-834, 2008.
39. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasina lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 58: 93-301, 2000.
40. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 59: 260-269, 2001.
41. Diamond JR, Karnovsky MJ. Focal and segmental glomerulosclerosis: analogic to atherosclerosis. Kidney Int 33: 917-924, 1988.
42. Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 41: 1341-1345, 2003.
43. Hsu CY, McCulloch CE, Darbinian J. Go AS, Iribarren C. Elevated blood Pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intent Med 165: 923-928, 2005.
44. Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 16: 763-773, 2005.
45. Kawamoto R, Ohtsuka N, Ninomiya D, Nakamura S, Carotid atherosclerosis in normal-weight metabolic syndrome. Intern Med 46: 1771-1777, 2007.